The binding properties of the disulˆde covalent bond between N-acetyl-L-cysteine (NAC) and human serum albumin (HSA) were investigated. HSA, puriˆed from either healthy subjects or renal failure patients, was incubated with NAC in buŠer and analyzed by 4VP-EG-Me column chromatography, which can distinguish between the redox states of the only free thiol of HSA. Although intact HSA was found to consist of mainly three sub-types, marcaptoalbumin (HMA), cysteine-bound nonmercaptoalbumin (HNACys) and a further oxidized form (HNAoxy), the formation of a new type of nonmercaptoalbumin (HNANAC) was conˆrmed after incubation with NAC. Interestingly, NAC rapidly dissociated Cys from HNA Cys and NAC itself bound very slowly to HSA. Theseˆndings suggest that the interaction between NAC and HSA proceeds in a 2-step processes. Theˆrst-order binding and dissociation rate constants of NAC to healthy HSA (kon,NAC) and Cys from healthy HNACys (koŠ,Cys) were approximately 0.003and 1.3 (h -1 ), respectively. On the other hand, HSA from renal failure patients showed decreased HMA and increased HNACys. The kon,NAC and koŠ,Cys were 0.0094 and 0.45 (h -1 ), respectively, suggesting that the pathological state may aŠect the binding properties of HSA and NAC.
Introduction
Human serum albumin (HSA) contains a free thiol that can interact outside of the albumin molecule and is derived from a cysteine residue at the 34th amino acid (Cys 34 ). 1) HSA can bind various thiol-containing compounds via a mixed-disulˆde bond, which forms between the free thiol of Cys 34 and a thiol from the other compound. Studies using various thiol-containing drugs have shown that the formation and degradation of such covalent bonds proceeds not instantaneously but timedependently and that the covalent-binding ratio between the thiol-containing drug and albumin varies with time. [2] [3] [4] [5] Therefore, elucidation of the properties of such protein-drug binding over time is an important pharmacokinetic issue in order to understand the e‹cacy of thiol-containing drugs.
We previously reported the kinetic proˆles of covalent binding between albumin and N-acetyl-Lcysteine (NAC), which is a thiol-containing drug used as a mucolytic agent, by determining the free-and proteinbound drug concentrations. 4, 5) On the other hand, Narazaki et al. have reported kinetic and mechanical proˆles of the binding between HSA and other thiolcontaining drugs, such as Captopril and Bucillamine, by directly detecting the conformational changes of the Cys 34 moiety of albumin using N-methylpyridinium polymer-based (4VP-EG-Me) column chromatography. 2, 3) In the present study, we directly quantiˆed HSA using a 4VP-EG-Me column after incubation with NAC and analyzed the kinetic properties of covalent protein binding in order to obtain basic information on the covalent binding between HSA and NAC. In addition, we investigated the eŠect of pathological conditions on binding kinetics of NAC using HSA puriˆed from the renal failure patients as well as the healthy subjects because the covalent protein-binding formation between HSA and thiol-containing drug, Bucillamine, increased in several pathological states, such as renal failure, diabetes, hepatitis, and rheumatism. 6) Methods Materials: HSA was purchased from Chemo-SeroTherapeutic Research Institute (Kumamoto, Japan) or puriˆed from human serum. Puriˆcation of albumin from human serum was performed according to the method of Watanabe et al. 7) Brie‰y, serum was applied to a Blue Sepharose a‹nity chromatography column, which was pre-treated with 0.2 M sodium acetate (pH 5.5). The column was then washed with 0.2 M sodium acetate (pH 5.5) and 1 N sodium chloride, and albumin was eluted with 0.02 M sodium acetate and 3 M sodium chloride (pH 6.5). The albumin containing fraction was dialyzed against water, freeze-dried, and de-fatted. Human serum: The protocol used in this study followed the tenets of the Declaration of Helsinki promulgated in 1964 and was approved by the institutional review board and informed consent was obtained from all subjects. Five stable hemodialysis patients (3 men and 2 women) aged 71 to 77 years, of dialysis age ranging from 5 to 9 years, were enrolled in the study. Five gender-matched healthy subjects were also investigated as a control group. End-stage renal failure was the result of glomerulonephritis (n＝5).
HPLC conditions: The HPLC system comprised an LC-4A pump (Shimadzu, Tokyo, Japan) equipped with a gradient programmer and a Shimadzu SPD-2AS ultraviolet (UV) monitor. The column packing material, N-methylpyridinium polymer cross-linked with ethylene glycol dimethacrylate (4VP-EG-Me), was prepared as described previously. 8) HSA was eluted using a 30-min linear gradient of 0 to 0.5 M sodium chloride in 0.05 M Tris-AcOH buŠer (pH 6.5) at a ‰ow rate of 0.5 mL W min at 259 C and the detection wavelength was 280 nm.
Deˆnition of HSA: HSA can be classiˆed into two main sub-types; mercaptoalbumin and nonmercaptoalbumin ( Fig. 1) . These sub-types are referred to as HMA and HNA, respectively. Although HNA is a general term that includes both the L-cysteine (Cys)-bound type and the oxidized type, HSA-Cys disulˆde and oxidized HSA are referred to as HNA Cys and HNA oxy , respectively in this study (Fig. 1 ).
Assay conditions: HSA was dissolved in phosphate buŠer (pH 7.4, 0.067 M, m＝0.15) from which endogenous oxygen had previously been removed by sonication and nitrogen replacement. The HSA solution (approximately 300 mM) was preincubated at 379 C for 5 min and then approximately 1500 mM NAC was added. The mixture was incubated at 379 C under anaerobic conditions. Aliquots were analyzed by HPLC at various incubation times.
For analysis of HSA incubated with 14 C-labelled NAC, column eluent was collected at 30-second intervals and the radioactivity of each fraction were determined.
Calculation of kinetic parameters: The reaction between HSA and low-molecular thiol-compounds was expected to proceed through the thiol-disulˆde exchange reaction. Possible mechanisms of the interactions between HSA, NAC, and Cys, which is the most abundant thiol-compound retained by HSA, are shown in Fig. 2 . The kinetic parameters koŠ,Cys, kon,Cys, and kon,NAC were deˆned as the apparentˆrst-order rate constants, representing the dissociation of Cys from HNACys, the binding of Cys to HMA, and the binding of NAC to HMA, respectively. These parameters were obtained as follows.
The concentrations of each sub-type of HSA were indicated as a percentage of each chromatographic peak against the total HSA peak area. The common logarithms of the concentrations were plotted against the incubation time and then correlation lines were obtained by the least-squares method. The slopes of these lines correspond to the rate constants (h -1 ) for the reactions.
Results
HPLC chromatogram of HSA: HSA was primarily separated into three sub-types (in order of abundance; HMA, HNACys, and HNAoxy) on the 4VP-EG-Me column chromatography (Fig. 3) . The ratio of three sub-types (HMA:HNA Cys :HNA oxy ) in HSA from healthy subjects was approximately 5:4:1 ( Fig. 3(a) ). On the other hand, HSA from renal failure subjects showed an extreme decrease in HMA and an increase in HNACys (Fig. 3(b) ).
Following incubation of HSA with NAC at 379 C, the HNACys peak was almost disappeared and a new peak was formed behind the HNAoxy peak (Fig. 3(c) ). When incubated with 14 C-labelled NAC, the radioactive peak corresponded to the newly formed peak (Fig. 4) , thus suggesting that the newly formed peak corresponded to the stable complex of HSA and NAC, i.e., HSA-NAC mixed disulˆde (HNANAC).
Time-courses of each HSA sub-type after incubation with NAC: Figure 5 shows the time-concentration plots of each albumin sub-type (HMA, HNA Cys , HNAoxy, and HNANAC) after incubation of healthy HSA with NAC. During the 2 hours from the start of incubation, HNACys rapidly decreased and HMA increased in a complementary manner, and this was followed by a slow reversal, with HNA Cys and HMA increasing and decreasing, respectively. These changes suggest that HNACys was rapidly divided into HMA and free Cys by NAC during theˆrst stage of incubation, and Cys then ), but the rate was greater in the dialysis patient HSA (approximately 0.01 (h -1 )). In contrast to these relatively low values, the dissociation rate constant of Cys from HSA (koŠ,Cys) was much greater in the commercial and healthy HSA (1.3 (h 
Discussion
The strong anion-exchange polymer N-methylpyridinium (4VP-EG-Me), developed by Sugii et al., is known to be able to separate HSA into its sub-types, which are classiˆed based on the redox state of the thiol function of Cys 34 . 9, 10) The mechanism of separation is presumed to depend on conformational diŠerences between HSA sub-types, which probably lead to a slight alteration in the electronic charge distribution on the surface of the molecule. 8, 10) In the present study, HSA was separated into three main sub-types (HMA, HNACys, and HNAoxy) as has been reported in previous studies. When HSA was incubated with NAC, a new peak was formed, thus suggesting the formation of a new type of HSA having a conformation diŠerent from the intrinsic HSA sub-types. In the 14 C-labelled NAC assay, it was shown that this new type of HSA tightly retains NAC. This new type HSA can thus be attributed to an HSA-NAC conjugate via the thiol function of Cys
34
. When comparing the present results withˆndings reported by Narazaki et al., in which the covalent binding of other thiol-containing drugs (Captopril and Bucillamine derivatives) to HSA was investigated, 2,3) the newly formed HSA-drug conjugates, including HSA-NAC, appeared after the HNAoxy peak. Thisˆnding is very interesting because the chemical structures of these thiol-containing drugs are quite diŠerent; the structure of NAC is similar to that of Cys. It is likely that HSA adopts a speciˆc conformation when a thiol-containing drug binds to Cys 34 , even if the structure of the drug diŠers.
The time-to-concentration proˆles of the HSA subtypes show that HNA Cys and HMA rapidly decreased and increased, respectively, immediately after the addition of NAC, while the HSA-NAC conjugate formed much more slowly. This observation suggests that NAC binds to HSA not directly but in a 2-step process. Speciˆcally, in step-1, NAC rapidly attacks the disulˆde bond of HNA Cys , resulting in dissociation of Cys and an increase in HMA. NAC probably binds preferably to Cys and forms NAC-Cys mixed-disulˆde at this time. In step-2, the low-molecular weight disulˆdes, such as NAC-Cys and probably NAC-NAC (diacetylcystine) as well as Cys-Cys (cystine), which were formed in the reaction mixture, slowly bind to the free-thiol of HMA and generate HSANAC or re-generate HNACys.
In the present study, the binding kinetics of NAC was investigated using HSA puriˆed from the renal failure patients as well as the healthy subjects in order to evaluate the pathological in‰uence on the binding. Because Narazaki et al. has reported that the covalent protein-binding between HSA and Bucillamine was negatively well correlated to the HMA content of renal failure patient's serum, whereas such good correlations were not obtained in other pathological states. 6) Accordingly, we selected the renal failure as an appropriate pathological state for the binding analysis.
The rate constants diŠerence between healthy and patient's HSA (Table 1) showed that the dissociation of Cys from HSA was suppressed in patients whereas the re-binding of Cys was not changed. This suggests that the high HNA Cys and low HMA content of the patient's HSA is probably due to suppressed dissociation of Cys from HSA. On the other hand, the binding of NAC to HSA was facilitated in patient's HSA. Why these changes occurred is not clear, but we have found that renal failure HSA resulted in a slight conformational change comparing with healthy HSA; (a-helical content: 63.3z for renal failure HSA, 67.8z for healthy HSA). Therefore, such conformational changes of renal failure patients' HSA may aŠect the binding and dissociation process of thiol-containing compounds through a structural change of the drug binding site, i.e. Cys 34 moiety of albumin. The present and previous 6) results suggest that an increase of covalent protein-binding formation in pathological state is common problem of thiol-containing drugs. Because such increase is thought to be mainly due to suppression of drug dissociation from albumin, the issues such as retardation of blood drug clearance, accumulation of drug in blood, and increase in blood level in repeated administration, should be considered in the therapy using thiol-containing drugs to patients. On the other hand, the free-thiol of Cys 34 of albumin is thought to be physiologically important because it may acts as a radical scavenger 11, 12) and a carrier of intrinsic various materials, such as metal ions.
1) Therefore, if thiol-containing drug highly occupies the free thiol of albumin in the pathological state, some unexpected adverse eŠect may occur.
With regard to drug-drug interactions, it is noteworthy that the dissociation of Cys from HSA induced by NAC occurs very rapidly. Because similar phenomena were observed in the reaction between HSA and both Captopril and Bucillamine derivatives, 2, 3, 6) it is believed that thiol-containing drugs can very rapidly dissociate Cys from HSA through a thiol-disulˆde exchange reaction. Such reactions would be more rapid in the serum than in the buŠer system because the thioldisulˆde exchange reaction is facilitated by factors such as dissolved oxygen and metal ions.
2) In fact, we have observed that the plasma free Cys level rapidly increased immediately after (2.5 min) an intravenous administration of pharmacological dose of NAC to rat. 13) This rapid``drive out'' eŠect of thiol-drugs on Cys is estimated to applicable to the interaction between thiol-drugs, i.e., the already bound thiol-drug will be dissociated rapidly by combining with another thiolcontaining compounds. Therefore, if a thiol-drug is used in combination with another thiol-drug in therapy, it should be considered that the free drug concentration of a thiol-drug may increase drastically after the administration of another thiol-drug.
In conclusion, we report that NAC interacts with HSA through a 2-step thiol-disulˆde exchange reaction. NAC rapidly reduces the disulˆde bond of HNA Cys and dissociates Cys from HSA, and it then binds to HSA much more slowly. Kinetic analysis has clariˆed that the covalent binding of NAC to HSA involves mechanical properties that are shared with other thiol-containing drugs and that the binding kinetics may be aŠected by pathological state.
